Pasithea Therapeutics Corp. (KTTAW) Net Equity Issued and Repurchased (2024 - 2026)

Pasithea Therapeutics has disclosed Net Equity Issued and Repurchased across 3 years of filings, most recently posting $358037.0 for Q2 2026.

• In Q2 2026, Net Equity Issued and Repurchased changed 0.0% year-over-year to $358037.0; the TTM figure through Jun 2026 stood at $783640.0 (changed N/A YoY), while the FY2025 annual figure was $2.1 million, down 53.99% from the prior year.
• Net Equity Issued and Repurchased came in at $358037.0 for Q2 2026 at Pasithea Therapeutics, up from -$2.1 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $4.5 million in Q3 2024 to a low of -$2.1 million in Q4 2025.
• Average Net Equity Issued and Repurchased over 3 years is $1.2 million, with a median of $1.0 million recorded in 2025.
• Year-over-year, Net Equity Issued and Repurchased plunged 51.03% in 2025 and changed 0.0% in 2026.
• Over 3 years, Net Equity Issued and Repurchased stood at $4.5 million in 2024, then slumped by 147.47% to -$2.1 million in 2025, then surged by 116.76% to $358037.0 in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $358037.0 in Q2 2026, -$2.1 million in Q4 2025, and $2.2 million in Q3 2025.